Rare ZMPSTE24 variants increase risk of hypertriglyceridemia and metabolic syndrome.

Bénédicte Toussaint, Nathalie Bonello-Palot, Alexandre Lourdelle, Brunot Creugnet, Céline Lukas Croisier, Camille Desgrouas, Emmanuel Buse Falay, Aurélie Dechaume, Emmanuel Vaillant, Martine Vaxillaire, Lauriane Le Collen, Mehdi Derhourhi, Souhila Amanzougarene, Brigitte Delemer, Philippe Froguel, Amélie Bonnefond, Catherine Badens

Journal: European journal of endocrinology 2025;192(3):240-247

PMID: 39993161

Abstract

OBJECTIVE

The global increase in the prevalence of metabolic syndrome represents a significant public health concern. Rare biallelic pathogenic variants in ZMPSTE24 have been identified as the cause of mandibuloacral dysplasia type B, ie, a lipodystrophy syndrome associated with metabolic complications. The role of monoallelic pathogenic variants in ZMPSTE24 concerning metabolic syndrome remains uncertain.

DESIGN

Case report and systematic review of literature.

METHODS

We investigated a Wallisian family with FPLD and metabolic syndrome via whole-exome sequencing. We performed functional analyses of an identified rare ZMPSTE24 variant. To broadly assess the effect of heterozygous pathogenic ZMPSTE24 variants on FPLD-associated phenotypes, and metabolic syndrome, we used the Human Gene Mutation Database (HGMD) and 200 K exome data from UK Biobank.

RESULTS

We investigated a Wallisian family where a 40-year-old female with metabolic syndrome was found to carry a rare heterozygous missense variant in ZMPSTE24. Functional assays showed a decreased prelamin to lamin A maturation and accelerated senescence. In silico analysis demonstrated that this variant might disrupt the lamin A binding site. We then analyzed the impact of monoallelic pathogenic ZMPSTE24 variants on metabolic traits using data from the HGMD and the UK Biobank. In HGMD, ZMPSTE24 variants carriers presented with dyslipidemia and hepatic steatosis. In the UK Biobank, monoallelic pathogenic variants were associated with an increased risk of hypertriglyceridemia, with a trend toward metabolic syndrome.

CONCLUSIONS

This study underscores the association of ZMPSTE24 rare variants with metabolic disorders and emphasizes the need for further research to clarify their clinical implications.

© The Author(s) 2025. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

Address: Inserm/CNRS UMR 1283/8199, Pasteur Institute of Lille, EGID, 59045 Lille, France.; University of Lille, Lille University Hospital, 59000 Lille, France.; Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, Nancy F-54000, France.; Aix Marseille Univ, Centre de recherche en Cardiovasculaire et Nutrition, INSERM, 13005 Marseille, France.; Department of Endocrinology Diabetology, University Hospital Center of Reims, 51092 Reims, France.; Diabetology Private Practice, 98800 Nouméa, France.; Inserm/CNRS UMR 1283/8199, Pasteur Institute of Lille, EGID, 59045 Lille, France.; University of Lille, Lille University Hospital, 59000 Lille, France.; Pediatric diabetology Department, American Memorial Hospital, University hospital, 51092 Reims, France.; Department of Endocrinology Diabetology, University Hospital Center of Reims, 51092 Reims, France.; CRESTIC EA 3804, UFR Sciences Exactes et Naturelles, Moulin de La Housse, BP 1039, 51687 Reims, France.; Aix Marseille Univ, Centre de recherche en Cardiovasculaire et Nutrition, INSERM, 13005 Marseille, France.; Laboratoire de Génétique Moléculaire, APHM, 13005 Marseille, France.; Inserm/CNRS UMR 1283/8199, Pasteur Institute of Lille, EGID, 59045 Lille, France.; University of Lille, Lille University Hospital, 59000 Lille, France.; Department of Metabolism, Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.